U.K. ad watchdog investigating Reckitt TV promo; Genmab exec throws cold water on dividend hopes;

@FiercePharma: China's Jiangsu Hansoh Pharmaceutical seeks $1.5B via HKEx IPO. FierceAsiaPharma story | Follow @FiercePharma

@EricPFierce: AstraZeneca closing Indian API plant that Swedish regulators slammed in an inspection report. FiercePharmaManufacturing story | Follow @EricPFierce

@CarlyHFierce: Roche challenges hometown rival Novartis with new targeted lung-cancer med Alecensa. More from FiercePharmaMarketing | Follow @CarlyHFierce

> Britain's advertising watchdog is investigating a Reckitt Benckiser TV ad for Nurofen Express pain tablets, saying it may have misled consumers with unfounded claims. Report

> The Danish drugmaker Genmab does not expect to pay a dividend in the near future because it sees a need to reinvest in its business, a company executive said. Report

> GlaxoSmithKline ($GSK) teamed up with Comic Relief in a 5-year partnership to fight malaria with grants to organizations working in five countries where the disease is endemic. Report | Release

Medical Device News

@FierceMedDev: ICYMI yesterday: Cleveland Clinic-partnered low-cost MRI provider nabs $6.5M to kick off national expansion. Article | Follow @FierceMedDev

@EmilyWFierce: ICYMI Friday: Lab experts lash out at move to beef up regulation of lab-developed tests. Article | Follow @EmilyWFierce

> Startup raises $5M to market next-gen nausea wearable to consumers. Article

> U.S., Israel commit $12M to develop next-gen tech for first responders. Story

> In latest Covidien deal synergy, Medtronic to build $14M manufacturing facility in Ireland. Report

Biotech News

@FierceBiotech: China's WuXi raises a $290M VC fund with eyes on 'cross-border' biotech bets. Article | Follow @FierceBiotech

@JohnCFierce: The 'big' model doesn't work in drug R&D, unless you're doing a big, focused PhIII program. . Source drugs. Focus. Gamble smart. | Follow @JohnCFierce

@DamianFierce: The 2015 Biotech IPO Boom, in Requiem. Watch | Follow @DamianFierce

> Kitov Pharma's combo arthritis drug clears Phase III with an FDA filing on deck. Article

> Bristol-Myers lends Opdivo to a combo with Neon's neoantigen attack on cancer. Story

> Ted Cruz's regulatory outsourcing plan for the FDA stirs controversy. Item

> What can Gilead, Biogen and Celgene teach Big Pharma about R&D? More

Pharma Manufacturing News

> AstraZeneca adding $113M packaging, warehouse facility in U.K. Report

> Sun Pharma shedding Ohio plant with sale to Nostrum Laboratories. Item

> Capsugel gets more manufacturing expertise with two-company deal. More

> Mylan wants some payback for plants it bought from Strides cited by FDA. Story

> Sweden says AstraZeneca used questionable asthma drug API from Indian plant. Article

Drug Delivery News

> Heat-enabled chemotherapy showing promise in studies. More

> More surgeons opt for spinal anesthesia in infants. Item

> Three-drug nanoparticle cuts back resistance in metastatic melanoma. Report

> Matinas' cochleate drug delivery candidate gets FDA's infectious disease product boost. Story

> Bind advances one arm of its lung cancer nanoparticle candidate, ditches another. Article

Pharma Asia News

> Fosun Group attempts to explain as high-profile chief detained by China authorities. Report

> China connection aids $280M in new funding for Pharmaron. Item

> China's Jiangsu Hansoh Pharmaceutical seeks $1.5B via HKEx IPO. Story

> As trade pacts sprout in Asia, medical device firms need to take note. Article

> Reckitt Benckiser ordered by Australian court to pull ibuprofen painkillers. More

And Finally... A surge of callers looking to sign up for health insurance under the Affordable Care Act temporarily overwhelmed the government's capacity to enroll consumers on Monday. Report

Suggested Articles

Lonza CEO Marc Funk is leaving for "personal reasons" after less than a year in the top job. 

Johnson & Johnson is chasing giants in its play for psoriatic arthritis with Tremfya. Strong data could help the newcomer convince the FDA.

Besting AbbVie's megablockbuster Humira is no laughing matter, but now Eli Lilly's Taltz has doubled up on head-to-head wins.